Certis Oncology Receives CLIA Recertification
Zero Deficiencies Noted by HHS Inspectors
San Diego, Calif. — November 18, 2024 – Certis Oncology Solutions, an AI-enabled precision oncology and translational science company, is pleased to announce that it has received notification from the U.S. Department of Health and Human Services (HHS) confirming the successful completion of its Clinical Laboratory Improvement Amendments (CLIA) inspection. This was the second recertification since the company first secured a CLIA license in 2018 and represents an uninterrupted record of HHS inspections resulting in “zero deficiencies”—a notable accomplishment for any regulated laboratory.
CLIA inspections, which are conducted by the Centers for Medicare & Medicaid Services (CMS), are a rigorous process designed to ensure clinical laboratories adhere to strict standards regarding test procedures, equipment, personnel qualifications, and quality control. The flawless inspection result highlights the company’s continuous investment in quality control measures and a dedicated team of scientists who prioritize precision.
“We are extremely proud of the company’s record for quality and regulatory compliance,” said Peter Ellman, Certis President and CEO. “This first-pass, zero observations CLIA re-certification is a testament to our team’s dedication, expertise, and unwavering commitment to delivering the highest level of science to our clients and the patients we serve.”
About Certis Oncology Solutions
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. The company’s product is Oncology Intelligence® — highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials.
Since its founding in 2016, Certis has offered personalized functional testing to help inform individual cancer treatment decisions, an approach gaining wide support from cancer researchers and oncology clinicians worldwide. Using our patent-pending artificial intelligence/machine learning platform and more clinically relevant, patient-derived tumor models, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry.
For more information about Certis, visit www.certisoncology.com.
MEDIA CONTACT
Certis Oncology Solutions
Kristein King
kking@certisoncology.com
573-818-4528